Development of novel tumor-specific PLGA microbubble ultrasound contrast media

• Project/Area Number: 24591809
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Gunma University
• Principal Investigator: TSUSHIMA Yoshito 群馬大学, 医学(系)研究科(研究院), 教授 (20375546)
• Research Collaborator: ACHMAD Arifudin 群馬大学, 大学院医学系研究科放射線診断核医学分野, 助教 (30757381)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: 超音波断層法 / 超音波造影剤 / マイクロバブル / 抗EGFR抗体 / Cetuximab / drug-delivery agent / ナノバブル

Outline of Final Research Achievements

The aim of this study was to develop a novel ultrasound contrast media which specifically accumulates into malignant tumors, and also acts as a drug-delivery agent. After several attempts, Cetuximab-labelled nanobubble (CTX-NB) was successfully synthesized. Cetuximab is the monoclonal antibody to the epidermal growth factor receptor (EFGR). CTX-NB has a shell of Poly-D,L-lactide-co-glycolide (PLGA), and contains perfluorooctyl bromide (PFOB). Specific accumulation and internalization of CTX-NB were microscopically confirmed in vitro using cultured EFGR-positive MDA-MB-231 human breast cancer cells.

Research Products

• [Journal Article] In vivo molecular imaging of cancer stem cells. (2015)
  • Author(s): Heryanto Y D, Achmad A, Taketomi-Takahashi A, TsushimaY
  • Journal Title: Am J Nucl Med Mol Imaging Volume: 5 Pages: 14-26
  • Peer Reviewed
• [Journal Article] Effects of intra-tumoral inflammatoroy process on 18F-FDG uptake: pathologic and comparative study with 18F-FAMT PET/CT in oral squamous cell carcinoma. (2015)
  • Author(s): Kim M, Achmad A, Higuchi T, Arisaka Y, Yokoo H, Yokoo S, Tsushima Y
  • Journal Title: The Journal of Nuclear Medicine Volume: 56 Issue: 1 Pages: 16-21
  • DOI: 10.2967/jnumed.114.144014
  • Peer Reviewed / Open Access
• [Journal Article] Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. (2014)
  • Author(s): Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, Oriuchi N, Endo K
  • Journal Title: Cancer Biotherapy & Radiopharmaceuticals Volume: 29 Issue: 2 Pages: 70-76
  • DOI: 10.1089/cbr.2013.1562
  • Peer Reviewed / Open Access
• [Journal Article] Current developments and clinical applications of bubble technology in Japan: a report from 85th Annual Scientific Meeting of The Japan Society of Ultrasonic in Medicine, Tokyo, 25-27 May, 2012. (2013)
  • Author(s): Achmad A, Taketomi-Takahashi A, Tsushima Y
  • Journal Title: Med Ultrason Volume: 15 Issue: 2 Pages: 140-146
  • DOI: 10.11152/mu.2013.2066.152.aa1att2
  • Peer Reviewed
• [Presentation] A Preliminary Report on EGFR-targeted PEGylated PLGA Immunonanobubbles as an Intratumor-specific targeted Ultrasound Contrast Agent (2012)
  • Author(s): Arifudin A, Yamaguchi A, Miyazaki M, Horisoko E, Takahashi A, Higuchi T, Tsushima Y.
  • Organizer: Progress in Radiology 2012
  • Place of Presentation: 東京